Effects of omalizumab in a patient with three types of chronic urticaria

are currently being edited and typeset. Readers should note that articles published below have been fully refereed, but have not been through the copy-editing and proof correction process. Wiley-Blackwell and the British Association of Dermatologists cannot be held responsible for errors or consequences arising from the use of information contained in these articles; nor do the views and opinions expressed necessarily reflect those of Wiley-Blackwell or the British Association of Dermatologists This article is protected by copyright. All rights reserved. Article Type: Case Report

[1]  P. Kuna,et al.  Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. , 2013, The Journal of allergy and clinical immunology.

[2]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[3]  O. Sarig,et al.  Digenic inheritance in epidermolysis bullosa simplex. , 2012, The Journal of investigative dermatology.

[4]  V. Adhami,et al.  Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise , 2012, Experimental dermatology.

[5]  Chang-Hun Lee,et al.  Defining keratin protein function in skin epithelia: Epidermolysis Bullosa Simplex and its aftermath , 2011, The Journal of investigative dermatology.

[6]  K. Schäkel,et al.  Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. , 2011, The Journal of allergy and clinical immunology.

[7]  P. Martus,et al.  IgE Mediated Autoallergy against Thyroid Peroxidase – A Novel Pathomechanism of Chronic Spontaneous Urticaria? , 2011, PloS one.

[8]  M. Jonkman,et al.  Mutations in KRT5 and KRT14 cause epidermolysis bullosa simplex in 75% of the patients , 2011, The British journal of dermatology.

[9]  R. Płoski,et al.  Gene dosage effect of p.Glu170Lys mutation in the KRT5 gene in a Polish family with epidermolysis bullosa simplex. , 2011, Journal of dermatological science.

[10]  T. Zuberbier,et al.  Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria , 2010, International Archives of Allergy and Immunology.

[11]  T. Krieg,et al.  Identification of novel and known KRT5 and KRT14 mutations in 53 patients with epidermolysis bullosa simplex: correlation between genotype and phenotype , 2010, The British journal of dermatology.

[12]  Li Cheng-xin,et al.  EAACI/GA2LEN/EDF/WAO Guideline:Management of Urticaria , 2010 .

[13]  M. Maurer,et al.  The definition and diagnostic testing of physical and cholinergic urticarias – EAACI/GA2LEN/EDF/UNEV consensus panel recommendations , 2009, Allergy.

[14]  H. Schünemann,et al.  EAACI/GA²LEN/EDF/WAO guideline: management of urticaria , 2009, Allergy.

[15]  H. Schünemann,et al.  EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria , 2006, Allergy.

[16]  E. Lane,et al.  Epidermolysis bullosa simplex in Scotland caused by a spectrum of keratin mutations. , 2007, The Journal of investigative dermatology.

[17]  T. Krieg,et al.  Novel and recurrent mutations in keratin KRT5 and KRT14 genes in epidermolysis bullosa simplex: implications for disease phenotype and keratin filament assembly , 2006, Human mutation.

[18]  T. Zuberbier,et al.  EAACI/GA2LEN/EDF guideline: management of urticaria , 2006, Allergy.

[19]  J. R. McMillan,et al.  Dominant and Recessive Compound Heterozygous Mutations in Epidermolysis Bullosa Simplex Demonstrate the Role of the Stutter Region in Keratin Intermediate Filament Assembly* , 2002, The Journal of Biological Chemistry.

[20]  D. Stevanović.  Inherited epidermolysis bullosa. , 1992, Journal of the American Academy of Dermatology.